EA201590732A1 - DISPENSABLE TABLET - Google Patents

DISPENSABLE TABLET

Info

Publication number
EA201590732A1
EA201590732A1 EA201590732A EA201590732A EA201590732A1 EA 201590732 A1 EA201590732 A1 EA 201590732A1 EA 201590732 A EA201590732 A EA 201590732A EA 201590732 A EA201590732 A EA 201590732A EA 201590732 A1 EA201590732 A1 EA 201590732A1
Authority
EA
Eurasian Patent Office
Prior art keywords
relates
dispensable tablet
tablet containing
tablet
dispensable
Prior art date
Application number
EA201590732A
Other languages
Russian (ru)
Inventor
Нилеш Танхаджи Думбре
Махеш Моханрао Бхадгале
Вардхаман Чандракант Бафна
Original Assignee
Азанта А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/680,216 external-priority patent/US8703188B1/en
Priority claimed from DK201270714A external-priority patent/DK177906B1/en
Application filed by Азанта А/С filed Critical Азанта А/С
Publication of EA201590732A1 publication Critical patent/EA201590732A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к таблетке, содержащей ниморазол. В частности, изобретение относится к фармацевтической композиции или таблетке, содержащей ниморазол или его фармацевтически приемлемую соль, для диспергирования в воде и введения через зонд пациенту с трудностями при глотании.The invention relates to a tablet containing nimorazol. In particular, the invention relates to a pharmaceutical composition or a tablet containing nimorazole or a pharmaceutically acceptable salt thereof, for dispersing in water and administering through a probe to a patient with difficulty in swallowing.

EA201590732A 2012-11-19 2013-11-18 DISPENSABLE TABLET EA201590732A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/680,216 US8703188B1 (en) 2012-11-19 2012-11-19 Dispersible tablet
DK201270714A DK177906B1 (en) 2012-11-19 2012-11-19 Dispersible tablet
PCT/DK2013/050384 WO2014075692A1 (en) 2012-11-19 2013-11-18 Dispersible tablet

Publications (1)

Publication Number Publication Date
EA201590732A1 true EA201590732A1 (en) 2016-01-29

Family

ID=49683383

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590732A EA201590732A1 (en) 2012-11-19 2013-11-18 DISPENSABLE TABLET

Country Status (12)

Country Link
EP (1) EP2919754A1 (en)
JP (1) JP2015537013A (en)
AU (1) AU2013347264B2 (en)
BR (1) BR112015011408A2 (en)
CA (1) CA2888856A1 (en)
EA (1) EA201590732A1 (en)
MX (1) MX2015006217A (en)
NZ (1) NZ707033A (en)
RU (1) RU2015117921A (en)
TN (1) TN2015000156A1 (en)
WO (1) WO2014075692A1 (en)
ZA (1) ZA201502896B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3250182B1 (en) * 2015-01-27 2023-04-26 Janssen Pharmaceutica NV Dispersible compositions
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070264330A1 (en) * 2006-05-15 2007-11-15 Bo Ragnar-Tolf Pharmaceutical formulations of pimavanserin
JP2008081448A (en) * 2006-09-28 2008-04-10 Kowa Pharmaceutical Co Ltd Bitterness masking rapid release particle of zolpidem tartrate
US20080131467A1 (en) * 2006-11-30 2008-06-05 Dennis Nelson Film-coated solid dosage form
TR201901905T4 (en) * 2009-12-11 2019-03-21 Sumitomo Dainippon Pharma Co Ltd Dry coated orodispersible tablet.
EP2558090A4 (en) * 2010-04-14 2013-05-08 Eupharma Pty Ltd Radiation sensitiser compositions

Also Published As

Publication number Publication date
MX2015006217A (en) 2015-11-16
JP2015537013A (en) 2015-12-24
WO2014075692A1 (en) 2014-05-22
TN2015000156A1 (en) 2016-10-03
NZ707033A (en) 2016-11-25
ZA201502896B (en) 2016-11-30
AU2013347264A1 (en) 2015-05-07
RU2015117921A (en) 2017-01-10
AU2013347264B2 (en) 2016-10-27
BR112015011408A2 (en) 2017-07-11
EP2919754A1 (en) 2015-09-23
CA2888856A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
MX351584B (en) Aqueous pharmaceutical formulation of tapentadol for oral administration.
UA106636C2 (en) MORPHOLINOTIAZOLES AS A POSITIVE ALLOSTERIC ALPHA MODULATORS 7
MX2014009757A (en) Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy.
IL223783B (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
IN2012DN06720A (en)
GB201106743D0 (en) Novel compounds
UA111717C2 (en) ORAL INTRODUCTION AND METHYLNALTREXON LIPOPHILIC SALTS
BR112012016853A2 (en) "pharmaceutical compositions for oral administration of insulin peptides".
MX356728B (en) Pharmaceutical combination for use in the treatment of diabetes type 2.
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
MX347105B (en) Pharmaceutical compositions comprising hydromorphone and naloxone.
PH12015500823A1 (en) Modified release formulations for oprozomib
MX344846B (en) Combination of active loaded granules with additional actives.
AR090073A1 (en) N-ETIL-N-PHENYL-1,2-DIHIDRO-4,5-DI-HYDROXI-1-METHYL-2-OXO-3-CHINOLINACARBOXAMIDE, ITS PREPARATION AND USES
EA201390950A1 (en) HOMOGENEOUS PHARMACEUTICAL ORAL DOSAGE FORMS CONTAINING LERKANIDIPIN AND ENALAPRIL OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS TOGETHER WITH ORGANIC ACID
EA201390417A1 (en) ANTI-DIABETIC SOLID PHARMACEUTICAL COMPOSITIONS
EA201591150A1 (en) SOLID UNIFORM FORM WITH HIGH CONTENT OF FEXOPHENADINE AND METHOD FOR OBTAINING IT
EA201590732A1 (en) DISPENSABLE TABLET
MX2013010947A (en) Gallium complexes, pharmaceutical compositions and methods of use.
EA201190282A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING TAMSULUS
MX363558B (en) Pharmaceutical compositions comprising flurbiprofen.
EA201201329A1 (en) NEW COMPOSITION FOR THE TREATMENT OF ESSENTIAL THROMBOCYTEMIA
EA201500446A1 (en) PHARMACEUTICAL COMPOSITION TO REDUCE N-OXIDE TRIMETYLAMINE LEVEL
EA201500368A1 (en) PHARMACEUTICAL COMPOSITION OF 1-ADAMANTYLETHYLOXY-3-MORFOLIN-2-PROPANOL OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR TREATING CARDIOVASCULAR PATHOLOGY
EA201291420A1 (en) ORAL MEDICAL FORMS CONTAINING LERCANIDIPIN AND ENALAPRIL AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS